Probiotic Bifidobacterium pseudocatenulatum converts hesperidin to hesperetin in aging mice
In naturally aging mice on a Western diet, six months of probiotic-derived hesperetin was reported to improve age-associated metabolic phenotypes; this is a mouse study, not evidence of human benefit. [1]
Automatic summary · not editorially reviewed
The key findings
The probiotic strain Bifidobacterium pseudocatenulatum CL256B converted hesperidin to hesperetin with about 90% bioconversion efficiency. [1]
In naturally aging mice on a Western diet, six-month treatment with probiotic-derived hesperetin was reported to improve age-associated metabolic phenotypes. [1]
The authors present the findings as support for a microbiome-enabled strategy activating the CISD2 longevity pathway to improve metabolic health during aging. [1]
The source at a glance
- Study type / format
- Preclinical mouse study (abstract)
- Population / context
- Naturally aging mice given a Western diet
- Summary based on
- Study abstract
- Original publication
- September 23, 2026
Hesperidin needs gut microbes to become hesperetin
The abstract explains that the citrus compound hesperidin is poorly absorbed in the intestine and depends on gut microbial conversion to its active form, hesperetin. Hesperetin activates CISD2, described as a pro-longevity gene whose expression declines with age. The researchers identified the probiotic strain Bifidobacterium pseudocatenulatum CL256B, which converts hesperidin to hesperetin through two enzyme activities and reached about 90% bioconversion efficiency.
Supporting source [1]
Metabolic changes in aging mice on a Western diet
In naturally aging mice given a Western diet, six-month treatment with probiotic-derived hesperetin was reported to improve age-associated metabolic phenotypes. These included lower body weight and adiposity, more lean mass, better muscle integrity and grip strength, and less hepatic steatosis. Glucose tolerance, insulin sensitivity and whole-body energy metabolism also improved. Liver analyses showed activation of SIRT1 and HNF4α signaling, and skeletal muscle showed restored ribosome homeostasis.
Supporting source [1]
Mouse findings do not establish human benefit
The abstract frames these results as support for a microbiome-enabled strategy in which probiotic-assisted conversion of hesperidin to hesperetin activates the CISD2 longevity pathway to improve metabolic health during aging. The reported improvements come from mice, so they do not show that the same effects occur in people. The abstract does not report sample sizes, a control comparison or safety data, and the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a mouse study, and the abstract reports no sample sizes, control comparison or safety data. The metabolic improvements in mice do not establish benefits for human aging.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Shen ZQ, Thuy TTD, Lu CK, Nguyen TS, Tung CY, Kao CY, Tsai TF. · europepmc.org · September 23, 2026